# OnCo record taiho-oncology (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/taiho-oncology/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "taiho-oncology" ;
  schema:name "Taiho Oncology (Otsuka)"@en ;
  schema:description "Taiho Oncology makes Inqovi, the oral decitabine-cedazuridine that in May 2026 became the first all-oral hypomethylating backbone for venetoclax in AML."@en ;
  schema:url <https://onco.cc/companies/taiho-oncology/>, <https://www.taihooncology.com> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-oral-combination-decitabine-and-cedazuridine-tablets-venetoclax-newly-diagnosed-acute> ;
  schema:addressCountry "JP" ;
  onco:cancers <https://onco.cc/cancers/aml/> ;
  onco:sections <https://onco.cc/fronts/epigenetics/> ;
  onco:drugs <https://onco.cc/drugs/decitabine-cedazuridine/>, <https://onco.cc/drugs/zipalertinib/> ;
  onco:trials <https://onco.cc/trials/nct06506955/> .